Protalix BioTherapeutics, Inc.

Develops plant-cell-based protein therapies for rare diseases like Gaucher and Fabry.

PLX | NYSE

Overview

Corporate Details

ISIN(s):: US74365A3095
LEI:
Country:: United States of America
Address:: 2 UNIVERSITY PLAZA, 7601 HACKENSACK
Website:: https://protalix.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Protalix BioTherapeutics, Inc. is an integrated biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins. The company leverages its proprietary ProCellEx® plant cell-based protein expression platform to create innovative medicines for rare diseases. Its end-to-end capabilities span from protein candidate selection and genetic engineering through preclinical/clinical development and commercial manufacturing. Protalix has successfully brought two enzyme replacement therapies to market: Elelyso for the treatment of Gaucher disease and Elfabrio for adult patients with Fabry disease. The company also actively seeks collaborations to develop new therapeutics for conditions with high unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Protalix BioTherapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Protalix BioTherapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Protalix BioTherapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Alpha Cognition Inc. Develops and commercializes novel treatments for neurodegenerative diseases like Alzheimer's and ALS.	United States of America	ACOG
Alteogen Inc. Biotech firm developing next-gen ADCs and biobetters with proprietary platform technologies.	South Korea	196170
ALTERITY THERAPEUTICS LTD Developing therapies for Parkinsonian disorders and MSA by inhibiting protein aggregation.	United States of America	ATHE
Alto Neuroscience, Inc. Developing precision medicines for depression and schizophrenia using a brain biomarker platform.	United States of America	ANRO
ALUMIS INC. Develops targeted oral therapies for immune-mediated diseases using precision immunology.	United States of America	ALMS
Alvotech Develops and manufactures affordable biosimilar medicines for patients worldwide.	United States of America	ALVO
Alvotech Holdings S.A Develops and manufactures affordable biosimilar medicines for global patient access.	Luxembourg	ALVO
ALX ONCOLOGY HOLDINGS INC Clinical-stage firm developing CD47 inhibitors for hematologic and solid tumors.	United States of America	ALXO
Alzamend Neuro, Inc. Developing lithium & vaccine therapies for neurodegenerative & psychiatric disorders.	United States of America	ALZN
Alzinova AB Developing targeted immunotherapies, including a vaccine, for Alzheimer's disease.	Sweden	ALZ